ASP 7962

Drug Profile

ASP 7962

Alternative Names: ASP7962

Latest Information Update: 21 Mar 2016

Price : $50

At a glance

  • Originator Astellas Pharma Europe Ltd
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain
  • Phase I Back pain

Most Recent Events

  • 01 Feb 2016 Phase-II clinical trials in Pain (due to osteoarthritis of the knee) in Belgium, Hungary (PO) (NCT02611466)
  • 01 Feb 2016 Phase-II clinical trials in Pain (due to osteoarthritis of the knee) in Czech Republic (PO)
  • 24 Nov 2015 Astellas Pharma plans a phase IIa trial for Pain (due to osteoarthritis of the knee) in Belgium, Czech Republic, Germany, Hungary, Spain and United Kingdom (PO) (NCT02611466)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top